Core Viewpoint - Altimmune, Inc. is under investigation for potential securities fraud following the release of mixed results from a clinical trial, which led to a significant drop in its stock price [1][2]. Group 1: Investigation and Legal Context - Pomerantz LLP is investigating claims on behalf of investors of Altimmune regarding possible securities fraud or unlawful business practices by the company and its officers or directors [1]. - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud [3]. Group 2: Clinical Trial Results and Market Reaction - On June 26, 2025, Altimmune announced "topline results" from the IMPACT Phase 2b trial of pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH), describing the results as "positive" [2]. - The trial reported fibrosis improvement rates of 31.8% and 34.5% for pemvidutide doses of 1.2 mg and 1.8 mg, respectively, compared to 25.9% for placebo, with the differences not being statistically significant [2]. - Following the announcement, Altimmune's stock price fell by $4.10, or 53.18%, closing at $3.61 per share on the same day [2].

Core Viewpoint - A class action lawsuit has been filed against Hims & Hers Health, Inc. concerning allegations of securities fraud and unlawful business practices [2][3]. Group 1: Lawsuit Details - The lawsuit involves claims that Hims & Hers and certain officers/directors engaged in securities fraud or other unlawful business practices [2]. - Investors who purchased Hims & Hers securities during the Class Period have until August 25, 2025, to request to be appointed as Lead Plaintiff [3]. Group 2: Partnership and Stock Impact - On April 29, 2025, Hims & Hers announced a collaboration with Novo Nordisk to sell a bundled offering of Wegovy® [3]. - On June 23, 2025, Novo Nordisk terminated its partnership with Hims & Hers, citing deceptive promotion and selling of illegitimate versions of Wegovy® that jeopardized patient safety [3]. - Following the termination announcement, Hims & Hers' stock price dropped by $22.24, or 34.63%, closing at $41.98 per share [3].

Group 1 - Edgewise Therapeutics is under investigation for potential securities fraud or unlawful business practices involving its officers and/or directors [1] - The company reported clinical trial data for its lead asset, sevasemten, indicating "positive" results for Becker and Duchenne muscular dystrophies, but the FDA deemed the data insufficient for accelerated approval [2] - Following the announcement, Edgewise's stock price decreased by $1.27 per share, or 8.86%, closing at $14.33 per share [3] Group 2 - Pomerantz LLP is a prominent firm specializing in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving PetMed Express, Inc. and its officers or directors [1] Group 1: Company Actions - On June 10, 2025, PetMed announced a delay in releasing its fourth quarter and fiscal year 2025 earnings due to the need for additional time to complete the year-end audit process [2] - Following the announcement, PetMed's stock price dropped by $0.47 per share, or 11.22%, closing at $3.72 per share on June 11, 2025 [2] Group 2: Legal Context - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for victims of securities fraud and corporate misconduct [3]

NEW YORK, June 27, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.The class action concerns whether Rocket and certain of its o ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Travere Therapeutics, Inc. and its officers or directors [1] Group 1: Company Developments - On May 15, 2025, Travere announced that the FDA plans to hold an advisory committee meeting regarding its supplemental New Drug Application for FILSPARI, aimed at treating focal segmental glomerulosclerosis [3] - Following the FDA announcement, Travere's stock price dropped by $4.35, or 20.57%, closing at $16.80 per share on May 16, 2025 [3] Group 2: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4] - The firm has successfully recovered numerous multimillion-dollar damages for class members over its 85-year history [4]

Core Viewpoint - Pomerantz LLP is investigating claims on behalf of investors of The Boeing Company regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1]. Group 1: Incident Overview - On June 12, 2025, a Boeing 787 Dreamliner operated by Air India crashed shortly after takeoff in Ahmedabad, India [3]. - Following the crash, Boeing's stock price decreased by $13.68 per share, representing a 6.39% decline, closing at $200.32 per share on June 13, 2025 [3]. Group 2: Legal Investigation - Pomerantz LLP is known for its expertise in corporate, securities, and antitrust class litigation, having a history of fighting for victims of securities fraud and corporate misconduct [4]. - The firm has successfully recovered numerous multimillion-dollar damages awards for class members over its 80-year history [4].

Group 1 - The investigation by Pomerantz LLP focuses on potential securities fraud or unlawful business practices by Proficient Auto Logistics, Inc. and its officers or directors [1] - Proficient Auto reported a 0.4% year-over-year decrease in total operating revenue to $95.2 million for the first quarter ended March 31, 2025, along with a total operating loss of $2.4 million [3] - Following the financial results announcement, Proficient Auto's stock price dropped by $0.40 per share, or 4.93%, closing at $7.72 per share on May 8, 2025 [3] Group 2 - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for victims of securities fraud and corporate misconduct [4] - The firm has a legacy of recovering multimillion-dollar damages awards for class members over its 80-year history [4]

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud and unlawful business practices by Groupon, Inc. and its officers or directors [1] Group 1: Investigation and Allegations - Pomerantz LLP is representing investors in an investigation regarding possible securities fraud by Groupon [1] - A report by short-seller Captain's Log on June 9, 2025, accused Groupon of questionable accounting practices and misleading investors about its turnaround success [3] - Following the allegations, Groupon's stock price dropped by $1.61, or 4.89%, closing at $31.33 per share on June 9, 2025 [3] Group 2: Company Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of over 85 years in fighting for victims of securities fraud [4]

Core Viewpoint - Designer Brands Inc. is under investigation for potential securities fraud and unlawful business practices following a significant drop in stock price after the company withdrew its 2025 guidance due to a challenging macroeconomic environment and declining consumer sentiment [1][3]. Financial Performance - On June 10, 2025, Designer Brands reported its financial results for Q1 2025 and announced the withdrawal of its 2025 guidance, attributing this decision to a "soft start to 2025" and "deteriorating consumer sentiment" [3]. - Following the announcement, Designer Brands' stock price decreased by $0.68 per share, representing an 18.23% decline, closing at $3.05 per share on the same day [3]. Legal Investigation - Pomerantz LLP is investigating claims on behalf of investors regarding potential securities fraud or other unlawful business practices by Designer Brands and its officers and/or directors [1].